Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors
This article was originally published in PharmAsia News
Executive Summary
Pfizer management, more bullish than the Street on long-term revenue forecasts for the combination of Pfizer and Wyeth, assured investors that incremental growth opportunities will emerge from the mega merger during a follow-up meeting with investors Jan. 27
You may also be interested in...
Japanese Pharmas Investing Heavily in Emerging Markets - BioJapan Conference
By 2030 the total pharma market size of BRIC countries, together with Mexico and Turkey, could reach $330 billion to $420 billion - almost equal to the combined market size of North America and Japan in 2006, which was $354 billion..
Japanese Pharmas Investing Heavily in Emerging Markets - BioJapan Conference
By 2030 the total pharma market size of BRIC countries, together with Mexico and Turkey, could reach $330 billion to $420 billion - almost equal to the combined market size of North America and Japan in 2006, which was $354 billion..
Pfizer To Become Largest Pharma In Japan After Wyeth Merger
Together, the two pharmas’ domestic drug sales top Takeda’s reining 6.1 percent market share.